21 May 2025
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non- Executive Director, has purchased 497,764 ordinary shares of 0.9p each ('Ordinary Shares') in the Company between 15 May 2025 and 20 May 2025 at a price of 9 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 130,884,801 ordinary shares representing 12.62% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||
| a) | Name | Vulpes Testudo Fund | |||||||||
| 2 | Reason for the notification | ||||||||||
| a) | Position/status | Fund closely associated with Martin Diggle, Non-Executive Director | |||||||||
| b) | Initial notification/Amendment | Initial notification | |||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a) | Name | Scancell Holdings plc | |||||||||
| b) | LEI | 2138008RXEG856SNP666 | |||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.9 pence each | |||||||||
| b) | Identification Code | GB00B63D3314 | |||||||||
| c) | Nature of the transaction | Purchase of Ordinary Shares | |||||||||
|
|
|
| |||||||||
| d) | Price(s) and volume(s) |
| |||||||||
| e) | Aggregated information - Aggregated volume - Price |
497,764 Ordinary Shares 9 pence per Ordinary Share | |||||||||
| f) | Date of the transaction |
| |||||||||
| g) | Place of the transaction | London Stock Exchange, AIM | |||||||||
| For further information, please contact: |
|
|
|
|
| Scancell Holdings plc | +44 (0) 20 3709 5700 |
| Phil L'Huillier, CEO |
|
| Sath Nirmalananthan, CFO |
|
| Dr Jean-Michel Cosséry, Non-Executive Chairman |
|
|
|
|
| Panmure Liberum (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
| Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
|
|
|
|
| WG Partners LLP (Joint Broker) David Wilson, Claes Spang | +44 (0) 20 3705 9330
|
|
|
|
| ICR Healthcare Mary-Jane Elliott, Stephanie Cuthbert, Chris Welsh | +44 (0) 20 3709 5700 |
About Scancell
Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by enhancing long-lasting tumour specific immunity. As a clinical stage biotechnology company with deep roots in cancer immunology and translational research, Scancell develops tumour targeted off-the-shelf vaccines, with highly favourable safety and durable systemic immune responses. Scancell's lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on top of checkpoint therapies in a multi-arm phase 2 study in first-line melanoma. The second vaccine, Modi-1, is being investigated in a phase 2 study in a broad range of solid tumours. Scancell is also developing a pipeline of high affinity antibodies targeting tumour specific glycans using its proprietary platforms. Two of these antibodies are now being developed in major biopharma partnerships, and a further two antibodies targeting lung and epithelial cancers are actively being developed in-house.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.